jama article week bankole johnson et al showing anticonvulsant topamax topiramate effective reducing percentage heavy drinking days placebo group topamax group double blind placebo controlled week study using study participants dose range mg daily side effects included tingling sensations changes taste loss appetite impairments concentration mean daily dose mg day started mg week mg day week increasing mg weekly divided morning night doses maximum mg may good approach helping people reduce drinking especially folks might also bipolar disorder sometimes also treated topamax study limitations first pattern adverse events similar found previous study rapid titration associated decreased study adherence taking medication previously topiramate titrated additional weeks ie weeks rather weeks retention rates similar topiramate placebo groups clinical sites least familiar topiramate experienced difficulties retention whereas completion rates among experienced groups approached data shown advise clinicians use slower titration schedule provide participants focused education managing emergent adverse events maximize adherence taking medication second clinical trials alcohol dependence field enrolled participants meet criteria enabling conduct safe study cohort often relatively healthier perhaps homogeneous general population seeking treatment alcohol dependence ability generalize without restriction trial clinical practice limited third study follow period could determine whether many interval participants would relapsed following medication withdrawal nevertheless respect people fare average following treatment alcoholism clinical trial meta analysis recent studies shown even single treatment event show substantial reductions drinking year afterward finding study topiramate safe consistently efficacious medication treating alcohol dependence scientifically clinically important alcoholism ranks third fifth global burdens disease respectively discovering pharmacological agents topiramate improve drinking outcomes make major contribution global health topiramate pharmacotherapy paired brief intervention deliverable nonspecialist health practitioners next step would examine efficacy community practice settings